ASH 2015: First-In-Class Myeloma Highlights
This article was originally published in Scrip
Executive Summary
A number of first-in-class products for acute myeloid leukemia and multiple myeloma provided clinical updates during the American Society for Hematology's (ASH) annual meeting, held Dec. 4-8 in Orlando, Florida.
You may also be interested in...
Agios, Celgene Target Accelerated Approvals For Precision AML Medicines
Celgene Corp. will pursue accelerated approval later this year for AG-221 (enasidenib), the lead drug candidate under its partnership with Agios Pharmaceuticals Inc., which may separately seek accelerated approval for its wholly-owned drug AG-120 in 2017, giving Agios's precision medicines a foothold in the oncology market while the collaborators work to expand the labeling for their drugs.
Agios Gets $200m Up Front In New Celgene Deal, Regains AG-120 Rights
Agios Pharmaceuticals Inc. will get $200m to kick off a new partnership with longtime collaborator Celgene Corp. under a complex agreement to develop therapies that alter the metabolic state of immune cells to enhance the immune response to cancer.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.